NEW YORK, May 14, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ('Seelos' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-8 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m.

2024年5月14日，纽约/PRNewswire/-Seelos Therapeutics，Inc.（纳斯达克：SEEL）（“Seelos”或“公司”）是一家临床阶段的生物制药公司，专注于开发中枢神经系统疾病和罕见疾病的治疗方法，今天宣布其董事会批准其已发行普通股的8股1股反向股票分割，自上午12:01起生效。

Eastern Time on Thursday, May 16, 2024..

东部时间2024年5月16日，星期四。。

The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, May 16, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol 'SEEL' with the new CUSIP number, 81577F307.

该公司的普通股将于2024年5月16日（星期四）开市时开始反向股票分割调整交易。在反向股票分割之后，该公司的普通股将继续在纳斯达克资本市场上交易，代码为“SEEL”，新的CUSIP编号为81577F307。

The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market..

反向股票分割旨在使公司重新遵守普通股每股1.00美元的最低出价要求，以便继续在纳斯达克资本市场上市。。

At the effective time of the reverse split, every 8 issued and outstanding shares of the Company's common stock will be converted automatically into one share of the Company's common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.

在反向分割生效时，公司普通股的每8股已发行和流通股将自动转换为公司普通股的一股，而每股面值不发生任何变化。不会发行与反向股票分割相关的零股，反向股票分割产生的零股将四舍五入到最接近的整股。

The reverse stock split will reduce the number of authorized shares of the Company's common stock from 400,000,000 shares to 50,000,000 shares and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. In addition, the reverse stock split will apply to the Company's common stock issuable upon the exercise of the Company's outstanding warrants and stock options, with proportionate adjustments to be made to the exercise prices thereof and under the Company's equity incentive plans, as applicable..

反向股票分割将使公司普通股的授权股数从400000000股减少到50000000股，除部分股份外，每位股东的所有权比例将保持不变。此外，反向股票分割将适用于行使公司已发行认股权证和股票期权后可发行的公司普通股，并根据公司股权激励计划（如适用）对其行权价格进行相应调整。。

The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 17.4 million to approximately 2.2 million.

反向股票分割将使公司普通股的已发行和流通股数量从大约1740万股减少到大约220万股。

About Seelos Therapeutics:

关于Seelos Therapeutics：

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington's disease, Alzheimer's disease, and Parkinson's disease.

Seelos Therapeutics，Inc.是一家临床阶段的生物制药公司，专注于开发和改进新型疗法，以满足中枢神经系统（CNS）疾病和其他罕见疾病患者未满足的医疗需求。该公司强大的投资组合包括针对严重抑郁症（MDD），肌萎缩侧索硬化症（ALS）和脊髓小脑共济失调（SCA）的急性自杀意念和行为（ASIB）等适应症的几个晚期临床资产，以及亨廷顿舞蹈病，阿尔茨海默氏病和帕金森氏病的早期计划。

.

.

Forward-Looking Statements:

前瞻性声明：

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the reverse stock split and the timing thereof, the potential impact of the reverse split on the bid price of the Company's common stock, the potential for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market and the expected number of shares of common stock to be outstanding following the reverse stock split.

本新闻稿中的声明不具有历史性，就1995年《私人证券诉讼改革法案》提供的安全港而言，构成前瞻性声明。这些声明包括关于反向股票分割及其时间安排的声明、反向股票分割对公司普通股出价的潜在影响、公司重新遵守在纳斯达克资本市场继续上市的普通股每股1美元最低出价要求的可能性以及反向股票分割后预期流通的普通股股数。

These statements are based on our current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties involved include those associated with general economic and market conditions, as well as other risk factors and matters set forth in our periodic filings with the SEC, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

这些声明基于我们目前的期望和信念，并受到许多因素和不确定性的影响，这些因素和不确定性可能导致实际结果与前瞻性声明中描述的结果存在重大差异。涉及的风险和不确定性包括与一般经济和市场状况相关的风险和不确定性，以及我们向SEC定期提交的其他风险因素和事项，包括我们最近的10-K表年度报告和随后的10-Q表季度报告。

Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise.

虽然我们认为前瞻性声明中反映的期望是合理的，但我们不知道我们的期望是否正确。请注意，不要过度依赖这些前瞻性声明，即使我们随后在我们的网站或其他网站上提供了这些前瞻性声明，这些声明仅在本协议签署之日起生效。

We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws..

我们不承担任何更新、修改或澄清这些前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，除非适用证券法可能要求。。

Contact Information

联系方式

Anthony MarcianoChief Communications OfficerSeelos Therapeutics, Inc. (Nasdaq: SEEL)300 Park Avenue, 2nd FloorNew York, NY 10022(646) 293-2136anthony.marciano@seelostx.com

Anthony MarcianoChief通信办公室Seelos Therapeutics，Inc.（纳斯达克：SEEL）300 Park Avenue，2nd FloorNew York，NY 10022（646）293-2136anthony.marciano@seelostx.com

Mike MoyerManaging DirectorLifeSci Advisors, LLC250 West 55th St., Suite 3401New York, NY 10019(617) 308-4306mmoyer@lifesciadvisors.com

Mike Moyer管理董事Lifesci Advisors，LLC250 West 55th St.，Suite 3401 New York，NY 10019（617）308-4306mmoyer@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-1-for-8-reverse-stock-split-302144966.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-1-for-8-reverse-stock-split-302144966.html

SOURCE Seelos Therapeutics, Inc.

来源：Seelos Therapeutics，Inc。